ADDEX THERAPEUTICS SA NAM.-AKTIE
ADDEX THERAPEUTICS SA NAM.-AKTIE/ CH0029850754 /
A0MSH6
11.09.2024 15:32:57
|
Zm.
-0,005
|
Wolumen |
Bid15:32:57 |
Ask15:32:57 |
Kapitalizacja Rynkowa |
St. dywidendy |
Wskaźnik C/Z |
0,075EUR
|
-6,52%
|
- Obrót: - |
0,075Wolumen Bid: - |
0,079Wolumen Ask: - |
13,37 mlnEUR |
- |
- |
Opis działalności
Addex Therapeutics (formerly Addex Pharmaceuticals Ltd.) is a biopharmaceutical company focused on the development of novel, orally available, small molecule allosteric modulators for neurological disorders. Allosteric modulators are an emerging class of small molecule drugs which have the potential to be more specific and confer significant therapeutic advantages over conventional "orthosteric" small molecule or biological drugs. Addex' allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention - the Addex pipeline has been generated from this pioneering allosteric modulator drug discovery platform. Addex's lead drug candidate, dipraglurant (mGluR5 negative allosteric modulator or NAM) has successfully completed a Phase 2a POC in Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID. In parallel, dipraglurant's therapeutic use in dystonia is being investigated. Addex's second clinical program, ADX71149 (mGluR2 positive allosteric modulator or PAM) is being developed in collaboration with Janssen Pharmaceuticals, Inc for epilepsy. In addition, ADX71441 (GABAB receptor PAM) program was awarded a $5.3 million grant by the US National Institute on Drug Abuse (NIDA, a division of National Institutes of Health (NIH)) to support human studies in cocaine addiction and has been licensed to Indivior. Discovery programs include mGluR4PAM, mGluR7NAM, mGluR3PAM and TrkBPAM.
Zarząd & Rada nadzorcza
CEO |
Tim Dyer |
Zarząd |
Lénaïc Teyssédou, Mikhail Kalinichev, Roger G. Mills |
Rada nadzorcza |
Dr. Vincent Lawton, Issac Manke, Jake Nunn, Raymond Hill |
Dane firmy
Nazwa: |
Addex Therapeutics Ltd |
Adres: |
12 Chemin des Aulx,CH-1228 Plan-les-Ouates / Geneva |
Telefon: |
+41-22-884-1555 |
Fax: |
+41-22-884-1556 |
E-mail: |
info@addextherapeutics.com
|
Internet: |
www.addextherapeutics.com |
Przemysł: |
Służba zdrowia |
Sektor: |
Produkty Medyczne |
Podsektor: |
Zaawansowane Urządzenia Medyczne |
Koniec roku finansowego: |
31.12 |
Free float: |
38,48% |
Data IPO: |
22.05.2007 |